Open-House-Biologika-Rabattverträge 2026-09 - Etanercept
Original notice title
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-09 - Etanercept
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No estimated value or volume provided, making it difficult to assess potential revenue.
This is not a public procurement under procurement law; disputes go to social courts, not procurement chambers.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- Techniker Krankenkasse
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Apr 29, 2028
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Apr 2028
- Conclusion of rebate agreements for the active substance Etanercept.
- Pharmaceutical products (CPV 33600000).
Show full summary
Open-house procedure for rebate agreements on the active substance Etanercept under §130a Abs. 8 SGB V. No exclusivity, uniform conditions, duration max 24 months from 01.05.2026 to 30.04.2028. Joining possible anytime.
Risks
No estimated value or volume provided, making it difficult to assess potential revenue.
This is not a public procurement under procurement law; disputes go to social courts, not procurement chambers.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) per §4 Abs. 18 AMG.
- Valid marketing authorization for Etanercept.
- Seat in Germany, EU, or EEA.
Requirements may be incomplete.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open-House-Biologika-Rabattverträge 2026-09 - Etanercept
Rebate agreements for Etanercept. Open to all eligible pharmaceutical entrepreneurs. No negotiation, uniform conditions.
Location
Duration
Category
Deadline
Award details
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Etanercept im Rahmen eines Open-House-Verfahrens.
Value note
Show original TED data
Original TED description
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Etanercept im Rahmen eines Open-House-Verfahrens.
Procurement Details
- Publication date
- 22 Mar 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 197229-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No estimated value or volume provided, making it difficult to assess potential revenue.
This is not a public procurement under procurement law; disputes go to social courts, not procurement chambers.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications